Home » Stocks » HTBX

Heat Biologics, Inc. (HTBX)

Stock Price: $1.06 USD -0.04 (-3.64%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $1.05 -0.01 (-0.94%) Dec 4, 7:58 PM

HTBX Stock Price Chart

Key Info

Market Cap 169.44M
Revenue (ttm) 4.34M
Net Income (ttm) -22.93M
Shares Out 143.73M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $1.06
Previous Close $1.10
Change ($) -0.04
Change (%) -3.64%
Day's Open 1.09
Day's Range 1.06 - 1.10
Day's Volume 3,611,831
52-Week Range 0.21 - 3.62

HTBX Stock News

Seeking Alpha - 1 month ago

Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.

InvestorPlace - 2 months ago

Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move T...

The Motley Fool - 3 months ago

COVID-19 vaccine stocks have gotten slammed this month.

Other stocks mentioned: AZN, BNTX, GSK, INO, JNJ, MRNA, NVAX, PFE, SNY, VXRT
The Motley Fool - 3 months ago

A pre-print is sending the biotech's shares higher today.

The Motley Fool - 3 months ago

Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

Other stocks mentioned: INO, NVAX
The Motley Fool - 3 months ago

Encouraging early results for the biotech's coronavirus vaccine have investors excited.

The Motley Fool - 3 months ago

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

Other stocks mentioned: DVAX, INO
The Motley Fool - 4 months ago

Heat Biologics and Vaxart could have a lot more room to run.

Other stocks mentioned: VXRT
The Motley Fool - 4 months ago

The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.

Benzinga - 5 months ago

Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.

Forbes - 6 months ago

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been thi...

Other stocks mentioned: BAND, COF, EYPT, GHSI
Forbes - 6 months ago

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...

Other stocks mentioned: BBI, DGLY, EYPT, MNKD

About HTBX

Heat Biologics, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2013
CEO
Jeffrey Wolf
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
HTBX
Full Company Profile

Financial Performance

In 2019, Heat Biologics's revenue was $3.05 million, a decrease of -47.37% compared to the previous year's $5.79 million. Losses were -$20.02 million, 27.2% more than in 2018.

Financial Statements